Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Tumor mutations and immune activity may reveal who benefits from investigational lymphoma drug (opens in a new tab)

medicalxpress.com · 2026-10-29

Short answerEvidenceSource

Short answer

Not assessed

Check incomplete.

We found a likely source study, but its evidence could not be prepared for claim review. The article's claims remain unverified.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Source study identified.

A source study was identified, but the study's evidence could not be prepared for claim assessment. No claim verdicts are available.

View article claims
3
Then inspect each claim

Evidence layer

Claim by claim

A source study was identified, but the study's evidence could not be prepared for claim assessment. The claims below have not been assessed.

Claim 1 of 5Not checkedResearchers at the University of Tsukuba conducted a physician-initiated phase 2 clinical trial of dasatinib in patients with relapsed or refractory T-follicular helper cell lymphoma (TFHL).View evidenceHide evidence

As stated17 patients

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 2 of 5Not checkedThe study identified genetic alterations and features of the immune microenvironment associated with treatment response, suggesting these factors may help identify patients more likely to benefit from dasatinib.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 3 of 5Not checkedClinical responses were observed in patients with mutations related to TCR signaling, along with clonal expansion of CD8-positive effector T cells and enhanced antitumor immune activity.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 4 of 5Not checkedPatients with a high burden of clonal hematopoiesis-associated mutations were less likely to benefit from treatment and showed impaired antitumor immune responses.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 5 of 5Not checkedThe work was published in Nature Communications and is described as potentially informing personalized treatment strategies and future immunotherapeutic approaches.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

A multi-center, single-arm, phase 2 trial of dasatinib in T follicular helper cell lymphomas

Nature Communications · 2026

Source record (opens in a new tab)

Why this one

Confident

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

Selected

A multi-center, single-arm, phase 2 trial of dasatinib in T follicular helper cell lymphomas

Nature Communications · 2026 · Crossref

Source (opens in a new tab)
Candidate

Specific cutaneous manifestations of nodal T‐follicular helper cell lymphoma, angioimmunoblastic type, and of other nodal T‐follicular helper cell lymphomas

Skin Lymphoma · 2026 · Crossref

Source (opens in a new tab)
Candidate

Peripheral T Cell Lymphoma with Follicular Helper Phenotype, Case Report and Literature Review

Haematology International Journal · 2019 · Crossref

Source (opens in a new tab)

And 10 more candidates considered.